# A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

> **NCT01152398** · PHASE1 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 15 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** MVA-BN-HER2

## Key facts

- **NCT ID:** NCT01152398
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01152398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01152398, "A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01152398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*